Virus-Fighting drug tested to protect vulnerable patients from RSV
NCT ID NCT06817889
Summary
This study is testing if the antiviral drug remdesivir can safely treat RSV (a common respiratory virus) in adults with weakened immune systems. Participants are people with cancer or autoimmune diseases who recently received treatments like stem cell transplants or specialized antibody therapies, which make fighting infections harder. The goal is to see if giving remdesivir early can prevent the RSV infection from becoming severe and requiring hospitalization.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
NOT_YET_RECRUITINGDuarte, California, 91010, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Conditions
Explore the condition pages connected to this study.